We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The full House of Representatives could vote on the 21st Century Cures Act as early as Thursday after the House Rules Committee meets to consider possible amendments to the bill. Read More
Toronto-based active pharmaceutical ingredient maker Attix Pharmaceuticals received an FDA warning letter due to lapses in current good manufacturing practices, including failure to appropriately package drug products to avoid cross contamination. Read More
Public health advocates called on the FDA Wednesday to expand access to the opioid overdose reversal drug naloxone by converting it from prescription-only to over-the-counter status. Read More
Public health advocates called on the FDA Wednesday to expand access to the opioid overdose reversal drug naloxone by converting it from prescription-only to over-the-counter status. Read More
The FDA is revoking general safety test requirements that are duplicative in biologics licensing applications and proposing to remove two obsolete regulations for the review and reclassification of biologics licensed before July 1972. Read More
A federal judge has ordered Apotex to pay AstraZeneca $98.5 million for infringing on patents to the latter’s heartburn drug Prilosec, following an appellate decision affirming most of a $76 million award from a 2013 ruling. Read More
Genentech, whose scleroderma treatment Actemra recently gained breakthrough therapy status from the FDA, topped the list of drugmakers making payments to physicians and teaching hospitals last year, with at least $274.2 million in general payments and $99.2 million in research payments covering more than 16,000 transactions. Read More